Iranian Journal of Public Health 2017. 46(8):1123-1131.

Survival Rates among Co-infected Patients with Human Immunodeficiency Virus/Tuberculosis in Tehran, Iran
Ghodratollah ROSHANAEI, Masoud SABOURI GHANNAD, Jalal POOROLAJAL, Minoo MOHRAZ, Leila MOLAEIPOOR

Abstract


Abstract

Background: The number of deaths related with co-infection of tuberculosis (TB) and HIV remains inappropriately high worldwide. TB is anticipated to be the major reason of HIV-related deaths globally. This study aimed to find out and evaluate the characteristics of the possible risk factors influencing the survival time of co-infected patients with HIV/TB in Tehran the capital of Iran.

Methods: This retrospective study was performed on the referred patients to the one of two Behavioral Diseases Coun­seling Centers, Imam Khomeini, and Zamzam Centers, Tehran, Iran, in 2004-2013. Data were analyzed by Cox PH model utilizing SPSS16 statistical software.

Results: Multivariate analysis confirmed that the age at diagnosis (P=0.014), gender (P=0.002), sexual transmission (P=0.01), cotrimoxazole preventive therapy (P<0.001), and onset to TB after post-HIV diagnosis (P=0.01) were the parameters which had significant effects on the death of HIV/TBco-infected patients.

Conclusion: The results, recommend interplay between different risk factors and the risk of death in co-infected patients with HIV/TB. We presented the barriers to higher-level organizational and functional integration for commitment to interfere with the modifiable risk factors, which effect on the mortality of patients.

 


Keywords


Acquired immunodeficiency syndrome; Human immunodeficiency virus; Tuberculosis; Risk factors; Survival Rate

Full Text:

PDF

References


Lessells RJ, Swaminathan S, Godfrey-Faussett P (2015). HIV treatment cascade in tuberculosis patients. Curr Opin HIV AIDS, 10(6):439-46.

Gupta RK, Lucas SB, Fielding KL, Lawn SD (2015). Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS, 29(15):1987-2002.

Hermans S, Horsburgh CR, Jr Wood R (2015). A Century of Tuberculosis Epidemiology in the Northern and Southern Hemisphere: The Differential Impact of Control Interventions. PLoS One, 10(8):e0135179.

Zenner D, Abubakar I, Conti S, et al (2015). Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland. Thorax, 70(6):566-73.

Bridge J, Hunter BM, Albers E, et al (2016). The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model (2002-2014). Int J Drug Policy, 27:132-7

Ghannad MS, Arab SM, Mirzaei M, Moinipur A (2009). Epidemiologic study of human immunodeficiency virus (HIV) Infection in the patients referred to health centers in Hamadan province, Iran. AIDS Res Hum Retroviruses, 25(3):277-83.

Tv Website (jamejamonline). (2012). http://www.jamejamonline.ir

Ministry of Health and Medical Education I.R. Iran. The status of TB/HIV Co-infection. (2011). Report of the Administration of Tuberculosis and Leprosy Control of the Ministry of Health and Medical Education I.R. Iran.

Ministry of Health and Medical Education (MOHME) (2011). National guideline for HIV/AIDS control and treatment. Tehran: MOHME. (Article in Persian).

World Health Organization. (2006).WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. http://www.who.int/hiv/pub/guidelines/hivstaging/en/

Roshanaei G, Sabouri Ghannad M, Saatchi M, et al(2014). Survival rates of human immunodeficiency virus and tuberculosis co-infected patients. Jundishapur J Microbiol, 7(6): e10565.

Mirani G, Williams PL, Chernoff M, et al (2015). Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy. Clin Infect Dis, 61(12):1850-61.

Organization WH. (2011). Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resourceconstrained settings. http://www.who.int/hiv/pub/tb/9789241500708/en/

Ayele HT, van Mourik MS, Bonten MJ (2015). Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study. BMC Infect Dis, 15:334.

Abay SM, Deribe K, Reda AA, et al (2015). The Effect of Early Initiation of Antiretroviral Therapy in TB/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. J Int Assoc Provid AIDS Care, 14(6): 560-570.

Poorolajal J, Molaeipoor L, Mohraz M, et al (2015). Predictors of progression to AIDS and mortality post-HIV infection: a long-term retrospective cohort study. AIDS Care, 27(10):1205-12.

Abdool Karim Q, Humphries H, Stein Z (2012). Empowering women in human immunodeficiency virus prevention. Best Pract Res Clin Obstet Gynaecol, 26(4):487-93.

Altice FL, Kamarulzaman A, Soriano VV, et al (2010). Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet, 376(9738):367-87.

Luetkemeyer AF (2010). Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States. Top HIV Med, 18(4):143-8.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.